摘要
目的:评价阿立哌唑治疗精神分裂症的有效性和安全性。方法:将52例精神分裂症患者,随机分配到阿立哌唑组26例和利培酮组26例,进行为期6周的随机双盲对照研究。采用阳性和阴性症状量表(PANSS)、临床疗效总评量表(CGI)、治疗中出现的症状量表(TESS)及有关实验室检查评定疗效和安全性。结果:治疗6周两组PANSS评分较治疗前均显著降低(P均<0.05),各时点PANSS评分两组间减分差异无统计学意义。治疗6周末,阿立哌唑组有效率58.3%,利培酮有效率75%,两组比较差异无统计学意义(χ2=1.50,P=0.221)。两组均未发生严重相关不良事件。阿立哌唑组对血清催乳素的影响较利培酮组小。结论:阿立哌唑治疗精神分裂症的疗效与利培酮相当,对催乳素无影响,是一种安全而有效的抗精神病药物。
Objective： To assess the efficacy and safety of aripiprazole on the treatment of schizophrenia. Method：A randomized, double-blind, double-dummy, comparative study was performed with a course of 6 weeks. Fifty-two Patients with schizophrenia were randomized into aripiprazole group （ n = 26 ） and risperidone group （n = 26）. The positive and negative syndrome scale （PANSS）, clinical global impression（ CGI）, treatment emergent symptom scale （TESS） were used to asess the effectiveness and the safety of the treatment. Results： By the end of the 6 week treatment, In both groups, the scores of PANSS decreased significantly comparing to the baseline （ P 〈 0.05 ） without statistically different between two groups. By the end of week 6, total clinical effective rates were 58.3% in aripiprazole group and 75% in risperidone group, without any statistically significant difference between the two groups. No severe adverse events were reported in both group. However, the influence on serum prolactin in aripiprazole group was much lower than in risperidone group. Conclusion： Aripiprazole has similar efficacy to risperidone in the antipsychotic treatment with mild impact on prolactin level. So aripiprazole is a safe and effective antipsychotics.
出处
《临床精神医学杂志》
2010年第1期35-37,共3页
Journal of Clinical Psychiatry
